Tutte le schermature portano a polo-like chinasi 1: Un nodo centrale nella terapia e nella resistenza al cancro.

Polo-like kinase 1 (PLK1) is a mitotic kinase that is frequently overexpressed across many cancer types and strongly associated with poor prognosis and resistance to treatment. Comprehensive genomic, genetic, and pharmacological screens consistently pinpoint PLK1 as a therapeutic target in oncology. Despite promising preclinical anti-tumor efficacy of PLK1 inhibitors, clinical outcome as a monotherapy has been modest, necessitating the development of next-generation PLK1 inhibitors and combination strategies. The role of PLK1 extends beyond cell cycle regulation to tumor progression, immune evasion, and the tumor microenvironment. Emerging evidence supports synergistic potential of new-gener